Neutron Delay to 2027 Now Likely, But Media Sees Dip as Buying Opportunity

What happened

A Motley Fool article published August 26, 2026, suggests that Rocket Lab's Neutron rocket could slip to 2027 but argues the delay may not materially impact the company's long-term story, framing the recent stock dip as a buying opportunity. However, the latest DeepValue master report, based on filings and earnings, shows that management has already weakened its language from a Q4 2026 first-launch target to only 'pad delivery' alignment with a narrowing launch window, indicating increased risk of further delay. The report highlights that Neutron is central to unlocking medium-lift revenue and national-security contracts, so a 2027 slip would push those catalysts further out, while gross margins remain guided at just 29-31% and adjusted EBITDA is negative. Additionally, CEO Peter Beck sold over 3 million shares in early July at prices above $80, which raises questions about insider conviction despite the positive public narrative. While the Fool article downplays the delay, the master report rates the stock a WAIT with an attractive entry around $60, well below the current price of $72.57, suggesting the dip may not yet be enough to warrant buying.

Implication

The Neutron schedule slip to 2027 would delay medium-lift revenue and defense credibility, directly impacting the bull case that hinges on timely execution. With Q3 guidance showing negative adjusted EBITDA and gross margin stuck at the low end, the company's profitability trajectory remains weak, and any further delay adds pressure. The CEO's large insider sales in July at higher prices signal a lack of urgency to defend the stock at current levels, which is a red flag for investors. While the Fool article frames the dip as a buying opportunity, the DeepValue report's WAIT rating and $60 attractive entry suggest the stock still has downside risk before becoming compelling. Therefore, investors should remain on the sidelines for now, monitoring for explicit Neutron first-flight disclosure and margin improvement before considering adding exposure.

Thesis delta

The thesis remains WAIT, but the news article reinforces the risk that Neutron slides into 2027, which would push out key revenue catalysts and weaken the case for medium-term upside. The article's attempt to frame the dip as a buying opportunity is not supported by insider actions or the company's near-term financial outlook. Consequently, the thesis does not shift to bullish; if anything, the delay risk increases the downside scenario probability, making the current valuation less attractive.